Most Read Articles
4 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
3 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 18 Nov 2020
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).

Vedolizumab, TNF blockers for IBD pose no new or recurrent cancer risk

6 days ago

Among inflammatory bowel disease (IBD) patients with a current or prior malignancy, treatment with vedolizumab (VDZ) or antitumour necrosis factor (anti-TNF) does not bear an increased hazard of developing new or recurrent cancer, as shown in a study.

The analysis included 463 IBD patients, among whom 96 patients were exposed to VDZ (mean duration, 1.7 person-years) after a diagnosis of cancer and 184 to anti-TNF (mean duration, 3.6 person-years). Some 183 patients received no immunosuppression therapy.

Half of the overall population had solid tumours as the primary cancer. Over a median of 6.2 person-years of follow-up, cancer events occurred in 18 patients on VDZ (new, n=7; recurrent, n=11), 61 patients on anti-TNF (new, n=27; recurrent, n=34), and 78 controls (new, n=30; recurrent, n=48). The corresponding incidence rates were 2.2, 4.2, and 5.6 per 1,000 person-years.

Multivariable Cox analysis revealed that the risk of developing new or recurrent cancer did not increase following exposure to VDZ (hazard ratio [HR], 1.38, 95 percent confidence interval [CI], 0.38–1.36) or anti-TNF therapy (HR, 1.03, 95 percent CI, 0.65–1.64) relative to no immunosuppression.

Analysis by biologic exposure time yielded similar results. Compared with anti-TNF, VDZ did not confer a risk increase in cancer events (HR, 0.82, 95 percent CI, 0.45–1.49).

The findings provide reassurance regarding the use of VDZ in the present population, as well as provide further evidence of the safety of anti-TNF therapy.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
3 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 18 Nov 2020
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).